Xcout Intel
Nura Bio
Nura Bio Inc. is a privately held biopharmaceutical company headquartered in South San Francisco, California, founded in 2018 to develop novel treatments for neurological diseases.
Subscribe to see Nura Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nura Bio at a glance
Nura Bio is a drug discovery company headquartered in United States. It has raised at least $140M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $73.8M in June 2026. Xcout tracks 10 named people at Nura Bio, including Shilpa Sambashivan (Chief Executive Officer).
Nura Bio leadership
- Shilpa SambashivanChief Executive Officer
- Lahar MehtaChief Medical Officer
- Scott GreenbergChief Business Officer
- Marc FreemanCo-Founder
- Steve McKnightCo-Founder
- Abe BassanBoard Member
4 more named people on record for Nura Bio, with roles, board committees and tenure — see the full roster →
Nura Bio funding rounds
At least $140M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $73.8M | 4 named | |
| Series A | $68M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Nura Bio competitors
A few of Nura Bio's closest competitors — see the full list of competitors and alternatives →
FundaMental Pharma is a biopharmaceutical spin-off established from Heidelberg University and headquartered in Heidelberg, Germany. Its research focuses on developing novel therapeutic approaches and treatments for neurological disorders.
Aneira Pharma, Inc. is a privately held pharmaceutical company founded in 2008 with its headquarters in San Diego, California.
Object Pharma is a privately held biopharmaceutical company headquartered in Aliso Viejo, California, founded in 2018. The company is dedicated to developing novel treatments for mental health disorders and manufactures botulinum toxin products for accredited research use.
Prazer Therapeutics is a biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company focuses on developing orally available, brain-penetrating small molecule therapeutics utilizing targeted protein degradation technology for novel drug discovery.
Neurasic Therapeutics is a Montreal-based drug discovery company founded in 2020 and based on research from McGill University's Montreal Neurological Institute. The company develops therapeutic solutions and medicinal drugs aimed at treating neurological disorders, with a primary focus on advancing opiate-sparing, pain-relieving treatments such as substituted thiophene for neuropathic and inflammatory pain.
Goldenrod Therapeutics, Inc. is a biotechnology innovator based in Houston, Texas, developing treatments for brain inflammation and PDE4B inhibitors for neurological conditions and substance use disorder.
Get Nura Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nura Bio in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access